ELAN (Elanco Animal Health) Research & Development: $371 Mil (TTM As of Mar. 2026)


ELAN Elanco Animal Health Inc ELAN
66 GF Score
Price $23.96
GF Value $15.57
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Elanco Animal Health Research & Development?

Elanco Animal Health ELAN +3.36% 66 Research & Development is $371 Mil as of Mar. 2026. GuruFocus rates ELAN with a GF Score™ of 66/100 and a GF Value™ of $15.57 (Significantly Overvalued). The stock has 2 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Elanco Animal Health's Research & Development for the three months ended in Mar. 2026 was $97 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $371 Mil.

Elanco Animal Health  (NYSE:ELAN) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Elanco Animal Health Research & Development Related Terms

Elanco Animal Health Research & Development Historical Data

* Premium members only.

The historical data trend for Elanco Animal Health's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Elanco Animal Health Research & Development Chart

Elanco Animal Health Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 369.00 321.00 327.00 344.00 368.00

Elanco Animal Health Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 94.00 92.00 89.00 93.00 97.00
ELAN
66GF Score
Elanco Animal Health Inc ELAN
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Elanco Animal Health Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $371 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $371 Mil mean?
Elanco Animal Health (ELAN) has a Research & Development of $371 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Elanco Animal Health and its competitors.
Is Elanco Animal Health's Research & Development too high?
Elanco Animal Health's current Research & Development is $371 Mil. Overall, Elanco Animal Health has a GF Score™ of 66/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Elanco Animal Health's Research & Development compare to RGC and NBIX?
Elanco Animal Health's Research & Development of $371 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Drug Manufacturers company?
A good Research & Development depends on the Drug Manufacturers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Elanco Animal Health and its competitors. Elanco Animal Health's current Research & Development is $371 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Elanco Animal Health stock overvalued right now?
Based on GuruFocus' analysis, Elanco Animal Health (ELAN) is currently considered Significantly Overvalued. The stock's GF Value™ is $15.57, compared to a current price of $23.96 — trading 53.9% above its estimated fair value. The current Research & Development is $371 Mil. Elanco Animal Health's overall GF Score™ is 66/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Elanco Animal Health (ELAN), the current Research & Development is $371 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Elanco Animal Health (ELAN) Overvalued in 2026?

Based on GuruFocus' analysis, Elanco Animal Health stock appears to be overvalued. The current stock price of $23.96 is trading 53.9% above its estimated GF Value™ of $15.57. GuruFocus considers Elanco Animal Health to be Significantly Overvalued.

Key valuation signals for ELAN:

  • Research & Development: $371 Mil
  • GF Value™: $15.57 vs. price of $23.96 (53.9% above fair value)
  • GF Score™: 66/100 with 2 warning signs

No single metric tells the full story. See the ELAN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Elanco Animal Health Business Description

Other Exchanges 5EA:Germany
Address 450 ELANCO CIRCLE, INDIANAPOLIS, IN, USA, 46221
Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, poultry, and swine production.
66GF Score

Get the complete analysis for ELAN

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$23.96
Price
$15.57
GF Value